Apyx Medical appoints two sales executives to support global expansion

CLEARWATER, Fla. - Apyx Medical Corporation (NYSE: APYX), currently trading at $1.98 and showing impressive momentum with a 102% return over the past year, has appointed two sales executives to its leadership team as part of its global expansion strategy and commercial launch of the AYON Body Contouring System.

John Featherstone has been named Vice President of North American Sales, bringing over 20 years of experience in commercial leadership roles within the aesthetics and medical device industry. He previously served as Vice President of Global Sales and Marketing at Cytrellis Biosystems and has held positions at Cutera, Inc. and Cynosure.

Simon Davies has been appointed Director of International Sales for Europe and Asia-Pacific. Based in Spain, Davies brings three decades of global sales leadership experience, having previously worked at Hewlett-Packard, Spacelabs Healthcare, and most recently as Director of Solta Medica in EMEA.

"The addition of John and Simon represents a significant milestone for Apyx as we continue to scale globally and bring groundbreaking solutions to market," said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical, according to the company’s press release.

Apyx Medical is an advanced energy technology company that manufactures Renuvion and the newly launched AYON Body Contouring System, which the company describes as the industry’s first all-in-one surgical body contouring system.

The appointments come as Apyx focuses on expanding its global presence and accelerating adoption of both its Renuvion and AYON products across North America, Europe, and Asia-Pacific regions. With a 45% price surge over the past six months, investors seeking deeper insights into Apyx’s financial health and growth prospects can access comprehensive analysis through InvestingPro, which offers exclusive financial metrics and expert research reports.

In other recent news, Apyx Medical Corporation reported its first-quarter 2025 earnings, exceeding analyst expectations. The company posted an earnings per share (EPS) of -$0.10, better than the anticipated -$0.12, and revenue reached $9.4 million, surpassing the projected $9.35 million. This financial performance has garnered attention from investors. Additionally, Apyx Medical has received FDA clearance for its AYON Body Contouring System, which is set to launch in the latter half of 2025. This system integrates multiple capabilities for body contouring procedures and uses the company’s Renuvion technology. The company also announced the launch of its Renuvion technology in China through a distribution agreement with GlamMoon Medical Technology. This partnership marks a significant step for Apyx Medical in expanding its presence in the Chinese market. These developments reflect the company’s ongoing efforts to innovate and expand its global footprint.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.